A single-pill treatment to suppress HIV proved as effective as existing therapies of up to 11 tablets daily, the latest advance in a scientific “golden age” for treating the virus even as rich ...

Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was generally well tolerated with low ...

Merck said a treatment it is developing for HIV-1 met its primary endpoint in three Phase 3 trials. The biopharmaceutical company said Wednesday the results add to growing evidence for ...

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), could effectively replace more complicated HIV treatment regimens used by people ...

Bictegravir is a global guideline-recommended integrase strand transfer inhibitor (INSTI) with a high barrier to resistance. INSTIs are a class of antiretroviral agents that target the viral integrase ...

The Philadelphia HIV Resource Finder allows Philadelphians to search for treatment and prevention resources throughout the city.

In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...

Zimbabwe is one of the world's first countries to roll out lenacapavir, a long-acting HIV prevention drug that is ...

Development assistance for health has fallen back toward 2010 levels, disproportionately disrupting community-based HIV services and projecting increased infections and AIDS-related deaths.

Melissa Schnure, PhD, wants to make sure some of the country’s most vulnerable patients are protected — low-income people living with HIV who depend on federally funded HIV services.It is why Schnure, ...

TACLOBAN CITY – The island town of Biri in Northern Samar has opened an HIV Treatment Hub to strengthen healthcare service ...

A new study led by researchers from the CUNY Institute for Implementation Science in Population Health (ISPH) finds that the ...